Tumor Antigen Presentation via Major Histocompatibility Complex Class I (MHC-I Presentation)

Tumor antigen presentation via major histocompatibility complex class I (MHC I) is a critical immunological process in which intracellular peptides, including those derived from tumor-specific or mutated proteins, are displayed on the surface of nucleated cells. This enables cytotoxic CD8+ T cells to recognize and eliminate abnormal or malignant cells. The pathway involves multiple components including MHC class I heavy chains, β2-microglobulin (β2M), proteasome/immunoproteasome subunits, transporter associated with antigen processing 1/2 (TAP1/TAP2), Tapasin, and Endoplasmic reticulum aminopeptidase 1 (ERAP1). Effective presentation is essential for anti-tumor immunity, and defects in this pathway are a common mechanism of cancer immune escape. It's also a critical step for immunotherapies that rely on CD8+ T cell responses.

Other names

MHC Class I Antigen PresentationHLA Class I Antigen PresentationTumor Antigen PresentationMHC-I Pathway

Checkpoint inhibitors enhance T cell activation by blocking inhibitory receptors; Interferons upregulate MHC-I expression and antigen processing; TLR agonists promote inflammation and antigen presentation.